Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | MASP2 | O00187 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23159233 | 0.73 | ADRA1D (0.38) | ADRA1DMASP2NR3C1NR3C2 | |
| SCHEMBL30748474 | 0.71 | ADRA1D (0.41) | ADRA1DMASP2NR3C1NR3C2 | |
| SCHEMBL16952222 | 0.70 | ADRA1D (0.40) | ADRA1DNR3C1NR3C2 | |
| SCHEMBL30646925 | 0.70 | ADRA1D (0.43) | ADRA1DNR3C1NR3C2 | |
| SCHEMBL2160824 | 0.70 | ADRA1D (0.43) | ADRA1DNR3C1NR3C2 | |
| SCHEMBL5959961 | 0.68 | ADRA1D (0.41) | ADRA1DNR3C1NR3C2 | |
| SCHEMBL29813213 | 0.67 | ADRA1D (0.45) | ADRA1DMASP2NR3C1NR3C2 | |
| SCHEMBL16953689 | 0.67 | ADRA1D (0.42) | ADRA1DNR3C1NR3C2 | |
| SCHEMBL26966869 | 0.67 | ADRA1D (0.45) | ADRA1DMASP2NR3C1NR3C2 | |
| SCHEMBL501685 | 0.67 | KDM4E (0.41) | ADRA1DNR3C1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4573077-A1 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024249252-A1 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024040235-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |